$481 Million is the total value of Aquilo Capital Management, LLC's 17 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 35.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPRO | Sell | SPERO THERAPEUTICS INC | $76,246,000 | +51.9% | 3,932,209 | -12.6% | 15.85% | +198.2% |
| IBB | New | ISHARES TRput | $75,710,000 | – | 500,000 | +100.0% | 15.74% | – |
| XBI | Sell | SPDR SER TRput | $70,406,000 | -84.2% | 500,000 | -87.5% | 14.63% | -69.0% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $42,618,000 | +19.2% | 380,012 | -1.5% | 8.86% | +134.0% |
| NGM | Sell | NGM BIOPHARMACEUTICALS INC | $30,463,000 | +88.0% | 1,005,534 | -1.3% | 6.33% | +269.2% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $29,859,000 | +20.7% | 1,355,392 | -1.4% | 6.21% | +137.1% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $28,078,000 | +24.6% | 365,926 | -30.1% | 5.84% | +144.6% |
| ANAB | Sell | ANAPTYSBIO INC | $26,143,000 | +19.9% | 1,215,958 | -17.7% | 5.43% | +135.5% |
| QURE | Buy | UNIQURE NV | $25,365,000 | +9.1% | 702,050 | +11.2% | 5.27% | +114.3% |
| RGNX | Sell | REGENXBIO INC | $22,836,000 | +62.5% | 503,444 | -1.4% | 4.75% | +219.0% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $17,769,000 | +172.6% | 2,266,423 | +136.4% | 3.69% | +435.2% |
| AMYT | New | AMRYT PHARMA PLCsponsored ads | $11,328,000 | – | 800,000 | +100.0% | 2.35% | – |
| PIRS | PIERIS PHARMACEUTICALS INC | $9,189,000 | +20.8% | 3,675,530 | 0.0% | 1.91% | +137.3% | |
| GLPG | Buy | GALAPAGOS NVspon adr | $6,928,000 | +50.1% | 69,989 | +115.1% | 1.44% | +194.5% |
| ARGX | Buy | ARGENX SEsponsored adr | $3,735,000 | +89.7% | 12,700 | +69.3% | 0.78% | +273.1% |
| GMAB | Buy | GENMAB A/Ssponsored ads | $3,659,000 | +99.8% | 90,000 | +80.0% | 0.76% | +291.8% |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $829,000 | – | 20,000 | +100.0% | 0.17% | – |
| ACIU | Exit | AC IMMUNE SA | $0 | – | -463,575 | -100.0% | -0.24% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -2,281,966 | -100.0% | -1.16% | – |
| IWM | Exit | ISHARES TR RUSSELL 2000put | $0 | – | -1,700,000 | -100.0% | -26.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.